Get started
Author

Yuka Hayakawa

ORCID: 0000-0002-3292-6794
Observed ORCID: 0000-0002-3292-6794
OpenAlex ID: A5103148093
Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease
2021 · Nobuharu Tamaki, Masayuki Kurosaki, et al. · Journal of Gastroenterology and Hepatology · 71
Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality
2021 · Mayu Higuchi, Nobuharu Tamaki, et al. · Alimentary Pharmacology & Therapeutics · 67
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
2020 · Sakura Kirino, Kaoru Tsuchiya, et al. · PLoS ONE · 66
PDF
Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis
2020 · Shun Kaneko, Kaoru Tsuchiya, et al. · Hepatology Research · 40
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
2019 · Wan Wang, Kaoru Tsuchiya, et al. · Cancers · 40
PDF
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin–bilirubin grade
2021 · Shun Kaneko, Masayuki Kurosaki, et al. · Hepatology Research · 31
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog
2020 · Sakura Kirino, Nobuharu Tamaki, et al. · Journal of Gastroenterology and Hepatology · 24
Hepatitis B core‐related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen‐negative chronic hepatitis B patients
2021 · Shun Kaneko, Masayuki Kurosaki, et al. · Journal of Gastroenterology and Hepatology · 23
Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib
2019 · Shun Kaneko, Kaoru Tsuchiya, et al. · Hepatology Research · 21
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
2019 · Hitomi Takada, Masayuki Kurosaki, et al. · Cancers · 20
PDF
Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
2019 · Nobuharu Tamaki, Masayuki Kurosaki, et al. · JGH Open · 17
PDF
Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
2021 · Kento Inada, Shun Kaneko, et al. · JGH Open · 15
PDF
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study
2022 · Yutaka Yasui, Masayuki Kurosaki, et al. · Cancers · 13
PDF
Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
2022 · Shuhei Sekiguchi, Kaoru Tsuchiya, et al. · Cancer Reports · 11
PDF
Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment
2021 · Sakura Kirino, Nobuharu Tamaki, et al. · Journal of Viral Hepatitis · 11
Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup
2020 · Nobuharu Tamaki, Masayuki Kurosaki, et al. · International Journal of Molecular Sciences · 11
PDF
Changes of liver stiffness measured by magnetic resonance elastography during direct‐acting antivirals treatment in patients with chronic hepatitis C
2020 · Mayu Higuchi, Nobuharu Tamaki, et al. · Journal of Medical Virology · 11
Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy
2020 · Hiroyuki Nakanishi, Yuka Hayakawa, et al. · Scientific Reports · 8
Validation of magnetic resonance elastography plus fibrosis‐4 for significant fibrosis in nonalcoholic fatty liver disease
2022 · Kento Inada, Nobuharu Tamaki, et al. · Journal of Gastroenterology and Hepatology · 7
Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib
2020 · Shun Kaneko, Kaoru Tsuchiya, et al. · JGH Open · 7
PDF
Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis
2020 · Nobuharu Tamaki, Masayuki Kurosaki, et al. · Hepatology Research · 6
Higher plasma prorenin concentration plays a role in the development of coronary artery disease
2015 · Gakuro Yoshida, Masanori Kawasaki, et al. · Biomarker Research · 6
PDF
Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan
2021 · Leona Osawa, Hiroyuki Nakanishi, et al. · Digestive Diseases · 5
The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy
2022 · Kenta Takaura, Masayuki Kurosaki, et al. · PLoS ONE · 4
PDF
A Case of Gastric Metastasis of Renal Cell Carcinoma Resected by Endoscopic Submucosal Dissection After Endoscopic Follow‐up of Morphological Changes
2025 · Yuichi Fukami, Nagako Nishihira, et al. · DEN Open · 2
PDF
Works count: 33
Citation count: 541
H-index: 13
I10-index: 17
Year
Topic
Type